research Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
Higher MPV and CRP levels may indicate more severe alopecia areata.
Search
for
Sort by
Research
810-840 / 1000+ results research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Pharmacophore Models for Toxicology Prediction
Pharmacophore models can predict liver toxicity and central nervous system toxicity, but they have limitations and specific requirements.
research 887: METHYLENE BLUE AS RESCUE THERAPY IN REFRACTORY HYPOTENSION FOLLOWING MINOXIDIL OVERDOSE
Methylene blue can effectively treat severe low blood pressure from minoxidil overdose when standard treatments fail.
research Nanoparticle Adjuvants Incorporating Haptens Drive Potent Immune Tolerance to Accelerate Hair Regrowth
Nanoparticles with specific drugs can help regrow hair in alopecia areata.
research Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
research Adverse events of dual anti-seizure medication: Real-life data from a tertiary epilepsy clinic
Dual anti-seizure medications, especially valproic acid with lamotrigine, often cause more side effects like hair loss and memory issues.
research Evaluation of Anthralin in the Treatment of Alopecia Areata
Anthralin cream helped 25% of patients with severe alopecia areata regrow hair, but caused skin irritation.
research Limits of Visual Detection for Finasteride Polymorphs in Prepared Binary Mixtures: Analysis by X‐ray Powder Diffraction
research Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
Baricitinib is effective and safe for treating severe alopecia areata.
research Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
research Efectos del minoxidilo en formulación oral en pacientes barosensibles
Careful monitoring is needed when using oral minoxidil for hair loss due to potential side effects.
research Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Skin reactions from cancer treatments might predict how well the treatments work.
research ODP056 The Treatment of Opioid Addiction Leading to Secondary Adrenal Insufficiency
Long-term treatment with buprenorphine/naloxone for opioid addiction may lead to secondary adrenal insufficiency.
research Postmarketing Surveillance of New Antiepileptic Drugs: The Tribulations of Trials
Monitoring new epilepsy drugs after they're sold is crucial to find rare and long-term side effects that initial tests might miss.
research Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
Reducing reactive oxygen species can help treat nerve damage from platinum cancer drugs.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Abstract 4993: A longitudinal examination of nutritional-inflammatory biomarker associations with cancer related cognition, treatment side effects and quality of life in newly diagnosed older adults undergoing chemotherapy
Certain blood markers can help predict and manage chemotherapy side effects in older cancer patients.
research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
research Adult patients with alopecia areata report a significantly better medication adherence compared to those with atopic dermatitis: Results from a large cross-sectional cohort study
Adults with alopecia areata stick to their medication better than those with atopic dermatitis.
research PLATELET-RICH PLASMA VS. MINOXIDIL IN ANDROGENETIC ALOPECIA: COMPARATIVE EFFECTIVENESS, SAFETY, AND PATIENT SATISFACTION – A SYSTEMATIC REVIEW
research PLATELET-RICH PLASMA VS. MINOXIDIL IN ANDROGENETIC ALOPECIA: COMPARATIVE EFFECTIVENESS, SAFETY, AND PATIENT SATISFACTION – A SYSTEMATIC REVIEW
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Abstract P5-21-05: ERALOP study: Post adjuvant FEC - docetaxel chemotherapy for early breast cancer: Hair regrowth in the real life
After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
research The Ability of Nutrient Antioxidants to Influence Oxidative Stress and Lower the Dose of Prednisolone in Patients with Alopecia Areata
Nutrient antioxidants helped reduce prednisolone dosage and improved hair growth in alopecia areata patients.
research Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis
Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
research Diphencyprone Induced Vitiligo: A Case Report
Diphencyprone can cause unexpected and possibly permanent vitiligo.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.